Institutional investors purchased a net $6.7 million shares of PGNX during the quarter ended March 2014 and now own 80.21% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BROADFIN CAPITAL LLC Bought 3.4 Million shares of Progenics Pharmaceuticals...